Moderna Prepares 2026-27 XFG COVID Booster as FDA Advisers Set to Vote
Reported by Wiseek News
Sentiment
Neutral
Importance
7
Price
$47.13
Mkt Cap
$18.661B
52W Low
$22.28
52W High
$59.55
Market data snapshot near publication time
Summary
Moderna is preparing its 2026-27 COVID booster, specifically targeting the XFG strain. FDA advisers are scheduled to vote on updating the vaccine strain, which is a crucial regulatory step for the company's core vaccine franchise. The outcome of this advisory committee vote will be a significant indicator for the booster's path to market and potential future revenue.
At the time of this announcement, MRNA was trading at $47.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.7B. The 52-week trading range was $22.28 to $59.55. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.
Price Chart
MRNA - Latest Insights
MRNA
Jun 01, 2026, 5:00 AM EDT
MRNA
May 27, 2026, 3:14 AM EDT
MRNA
May 14, 2026, 3:54 AM EDT
MRNA
May 13, 2026, 4:04 PM EDT
MRNA
May 08, 2026, 4:06 PM EDT
MRNA
May 06, 2026, 5:00 PM EDT
MRNA
May 01, 2026, 4:10 PM EDT
MRNA
May 01, 2026, 4:06 PM EDT
MRNA
May 01, 2026, 6:30 AM EDT
MRNA
Apr 21, 2026, 9:40 AM EDT